Association analysis between variants of the interleukin-1β and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This study investigated the possible association of the interleukin-1 beta (IL-1beta) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)(n) variable number of tandem repeats (VNTR) polymorphism with antidepressant response to paroxetine and mirtazapine treatment. The study group consisted of 101 patients suffering from DSM-IV major depression participating in a randomized double-blind controlled clinical trial. Patients homozygous for the IL-1beta-511T allele had a significantly faster and more pronounced response to paroxetine treatment than IL-1beta-511C allele carriers. No association was found for the IL-1beta C-511T polymorphism with mirtazapine treatment response. The IL-1Ra VNTR showed neither an association with paroxetine nor with mirtazapine treatment response. Our results provide further suggestive evidence that time course of response and antidepressant efficacy of paroxetine, but not of mirtazapine, is influenced in a clinically relevant manner by the IL-1beta C-511T gene variant. Our data do not support the hypothesis that the IL-1Ra (86bp)(n) VNTR affects antidepressant treatment response to paroxetine or mirtazapine. An independent replication of our finding is needed. If replicated, the IL-1beta C-511T promoter polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 1×
“However, the multiplicity of possible mechanisms of immune modulation by antide-pressants (Schiepers et al 2005) suggests that several other reasons might be involved.”
Zhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549 · cited 1×
“IL-1β has been shown to up-regulate hippocampal expression of the 5-HT transporter (Ramamoorthy et al 1995) and to activate neuronal 5-HT (Zhu et al 2006).”
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398 · cited 2×
“…between genotype groups across the treatment period were analyzed using a mixed-effects model repeated-measures methodology (MMRM), as MMRM has been shown to provide highly accurate modeling of treatment outcome while accounting for nonrandom missing data (Mallinckrodt et al 2001, 2003).”
InfluentialLicinio, J., & Wong, M.-L. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000586 · Cited by 380 · cited 4×
“Several studies support a neuroprotective function of IL-1Ra (Licinio and Wong 1999), which is constitutively expressed in brain (Licinio et al 2007).”
InfluentialEffects of antidepressants on the production of cytokines
Kenis, G., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003164 · Cited by 370 · cited 3×
“Among the cytokines, animal and clinical studies have demonstrated that interleukin 1beta (IL-1 β ) may have a key role in major depression and in the effects of antidepressant treatment (Licinio and Wong 1999; Kenis and Maes 2002).”
Hayley, S., Poulter, M. O., Merali, Z., & Anisman, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.051 · Cited by 324
Effects of Cytokines on Cerebral Neurotransmission: Comparison with the Effects of Stress
Dunn, A. J., Wang, J., & Ando, T. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_8 · Cited by 316 · cited 1×
“Systemic administration of IL-1 in rats increased dopamine (DA), norepinephrine (NE), and serotonin (5-HT) activities in hypothalamic nuclei, nucleus accumbens, and limbic regions including the hippocampus (Merali et al 1997; Anisman and Merali 1999; Dunn et al 1999; Song et al 1999).”
Increase in Interleukin-1β in Late-Life Depression
Thomas, A. J., Davis, S., Morris, C., Jackson, E., Harrison, R., & O’Brien, J. T. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.175 · Cited by 291
Maier, S. F., & Watkins, L. R. (1995) · Brain Research · doi:10.1016/0006-8993(95)00930-o · Cited by 178
Inflammatory markers in major depression and melancholia.
Rothermundt, M., Arolt, V., Peters, M., Gutbrodt, H., Fenker, J., Kersting, A., & Kirchner, H. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00157-9 · Cited by 174
Song, C., Merali, Z., & Anisman, H. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00271-1 · Cited by 172
Regulation of the Human Serotonin Transporter by Interleukin-1β
Ramamoorthy, S., Ramamoorthy, J. D., Prasad, P. D., Bhat, G. K., Mahesh, V. B., Leibach, F. H., & Ganapathy, V. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2659 · Cited by 156
Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D., & Pollmächer, T. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-36390 · Cited by 144
Obuchowicz, E., Kowalski, J., Labuzek, K., Krysiak, R., Pendzich, J., & Herman, Z. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500547x · Cited by 115 · cited 1×
“If some of the effect of SSRIs is to diminish the production of central or peripheral proinfl ammatory cytokines such as IL-1 (Yirmiya et al 2001; Castanon et al 2004; Obuchowicz et al 2006) the response to SSRIs could indeed be greater in IL-1 β -511TT carriers.”
Kast, R. E. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00093-8 · Cited by 62
Suzuki, E., Shintani, F., Kanba, S., Asai, M., & Nakaki, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12985-2 · Cited by 55
Pharmacogenomics of neuroimmune interactions in human psychiatric disorders
Licinio, J., Mastronardi, C., & Wong, M. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2007.038471 · Cited by 23
Cited by
NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings
Kaufmann, F. N., Costa, A. P., Ghisleni, G., Diaz, A. P., Rodrigues, A. L. S., Peluffo, H., & Kaster, M. P. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.03.002 · Cited by 370
“…homozygous for the −511C allele exhibited increased severity of depressive symptoms, poor response to fluoxetine and paroxetine, and earlier age of onset for geriatric depression when compared to the other genotypes (Yu et al., 2003; Tadic et al., 2008; Hwang et al., 2009; Tarter et al., 2015).”
A Dialogue between the Immune System and Brain, Spoken in the Language of Serotonin
Baganz, N. L., & Blakely, R. D. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300186b · Cited by 309
Genetics Factors in Major Depression Disease
Shadrina, M., Bondarenko, E. A., & Slominsky, P. A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00334 · Cited by 288
Genetic Contributions of Inflammation to Depression
Barnes, J., Mondelli, V., & Pariante, C. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.169 · Cited by 237
Bufalino, C., Hepgul, N., Aguglia, E., & Pariante, C. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.009 · Cited by 228
“In line with this report, Tadic et al. (2008) demonstrated that the IL-1b 511(C/C) genotype showed a slower and less pronounced response to paroxetine than patients with the IL-1b 511(C/T) or 511(T/T) genotype.”
Influential
Metadata
- Authors
- Tadic, A.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2008-03
- Volume
- 4
- Issue
- 1
- Pages
- 269
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2038316458
- Cited by
- 35
- References
- 17
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.